UltraCAR-T is under clinical development by SaxoCell and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UltraCAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UltraCAR-T overview
The therapeutic candidate is under development for the treatment of acute myelocytic leukemia (AML). It comprises of T-cells which are genetically engineered to express chimeric antigen receptors (CAR) targeting tyrosine kinase receptor related 1 (ROR1) expressing cells. It is being developed based on Sleeping Beauty platform technology.
SaxoCell overview
SaxoCell is engaged in research and development of gene and cell therapies for the treatment of tumors and autoimmune diseases. The company is headquartered in Dresden, Sachsen, Germany.
For a complete picture of UltraCAR-T’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
